About Multiply Labs
Multiply Labs makes robotic clusters that automate the manual steps of biologics manufacturing. The work spans cell and gene therapies, antibodies, viral vectors and mRNA therapies. Robotic arms run each step inside a closed, GMP-ready system with sterile conditions. Its software executes the customer's manufacturing protocol and logs each sensor reading and interaction as it happens. Complete electronic records go straight to the customer and its quality system. Pharmaceutical and biologics companies own and operate the clusters themselves.
Multiply Labs was founded in 2016 as a Y Combinator startup and is based in San Francisco. Fred Parietti is co-founder and chief executive officer, and Alice Melocchi is co-founder and CSO. Manny Guerrero is chief financial officer. Enrico Racca is chief supply chain and manufacturing officer. The team has 65 people and one robot. In October 2026 the company announced a $75 million Series B led by NantWorks.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 26, 2025 | Nov 5, 2026 | $52,250,260fully sold | 22 | $2.3M | EquityRule 506(b) | Form D ↗ |
| Apr 10, 2023 | Apr 24, 2023 | $11,100,000fully sold | 4 | $2.7M | Debt, Options, Convertible Promissory NotesRule 506(b) | Form D ↗ |
| Apr 5, 2021 | Apr 20, 2021amended Apr 21, 2021 | $25,037,515fully sold | 61 | $410K | Equity, Series A Preferred Stock and Series A-1 through Series A-10 Preferred StockRule 506(b) | Form D/A ↗1 earlier filing |
| Oct 27, 2018 | Mar 16, 2021 | $2,252,500fully sold | 17 | $132K | Options, Simple Agreement for Future EquityRule 506(b) | Form D ↗ |
| Jun 6, 2016 | May 11, 2017 | $2,805,000fully sold | 34 | $82,500 | EquityRule 506(b) | Form D ↗ |
| Total, five offerings | $93,445,275 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by Multiply Labs
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Oct 6, 2026 | Series B | $75 million | NantWorks (lead), AstraZeneca, Lingotto, Teradyne, Strange Ventures, Casdin Capital, Lux Capital, Fifty Years, Ora Global, Founders Fund | Multiply Labs press release ↗ |
Why Investors Backed Multiply Labs
Multiply Labs sells robotic clusters that automate sterile biologics manufacturing for drug companies. It announced a $75 million Series B on October 6, 2026, led by NantWorks. The company plans to use the money to expand manufacturing capacity, speed up its product roadmap and add staff in engineering, regulatory and commercial roles.
The problem it targets
Multiply Labs argues that some of the most complex steps in biomanufacturing remain largely manual. Biologics manufacturing has dozens of discrete steps, each needing a closed sterile environment and repeatable handling. It adds that a single contamination event can cost millions of dollars and delay access to medicine.
What the product does
Each cluster plugs into a customer's existing instruments and processes. That means no new facility and no change to practices already validated. Multiply Labs cites a 74% cut in cost per dose and up to 100 times the throughput of manual manufacturing. It calls the system autonomous: it learns, adapts and runs continuously. The platform began with cell and gene therapy and is expanding to antibodies, viral vectors and mRNA.
Progress so far
Total capital raised has passed $100 million since the company's 2016 founding. Its deployments so far are clinical-stage, and the new capital is meant to build toward commercial-scale production. In January 2026, Multiply Labs announced an agreement with AstraZeneca to evaluate its GMP-ready robotic systems for commercial-scale cell therapy manufacturing. The newest systems use four robotic arms in parallel to run instruments that the industry already uses.
Who backs it
Dr. Patrick Soon-Shiong of NantWorks led the round. New investors are AstraZeneca, Lingotto, Teradyne and Strange Ventures. Returning investors include Casdin Capital, Lux Capital, Fifty Years, Ora Global and Founders Fund. Ileana Pirozzi of Lingotto Innovation is a member of Multiply Labs' board of directors. She said she believes robotics can change biomanufacturing the way it changed automotive and semiconductor production.
How the market is moving
Multiply Labs' release says tens of billions of dollars are going into AI drug discovery, while manufacturing timelines have barely changed. That is the company's view of the gap it targets. Pirozzi gave a related view. She said that as the pipeline of advanced therapies grows, producing them efficiently and at scale increasingly limits how many patients can get them, and at what cost.
We wrote this summary from public statements by Multiply Labs and its investors. It is not investment advice.
Multiply Labs in the News
Leadership Team
Executive officers and directors listed on Multiply Labs's Form D filed Nov 5, 2026.
Earlier filings also listed Shaun Rodriguez (director, last listed Apr 2023), Jason Arcediano (executive officer, last listed Apr 2023), Alice Melocchi (executive officer, last listed Apr 2023), Tiffany Kuo (director, last listed May 2017) and Joseph Wilson (secretary, director, last listed May 2017).